Evidence map›Paper›PMID 40683250›Full record

ArticleCurrent biology : CB2025

Reprogramming of endolysosomes for melanogenesis in BLOC-1-deficient melanocytes.

Philip S Goff, Shyamal Patel, Dawn C Harper, Tom Carter, Michael S Marks, Elena V Sviderskaya

Abstract read
In one paragraph

Article in Current biology : CB, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Philip S GoffSchool of Health and Medical Sciences, City St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Shyamal PatelSchool of Health and Medical Sciences, City St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Dawn C HarperDepartment of Pathology & Laboratory Medicine, Children's Hospital of Philadelphia Research Institute, Philadelphia, PA 19104, USA.
Tom CarterSchool of Health and Medical Sciences, City St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Michael S MarksDepartment of Pathology & Laboratory Medicine, Children's Hospital of Philadelphia Research Institute, Philadelphia, PA 19104, USA; Department of Pathology & Laboratory Medicine and Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: marksm@pennmedicine.upenn.edu.
Elena V SviderskayaSchool of Health and Medical Sciences, City St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK. Electronic address: esviders@citystgeorges.ac.uk.

Funding

Hermansky Pudlak Syndrome &melanosome formationR01EY015625 · NEI · UNIVERSITY OF PENNSYLVANIA · PI Michael S Marks · 2004 to 2026
$9.2M
NEI NIH HHS R01 EY015625Wellcome Trust
6 · The paper itself

Abstract

Photoprotective melanins in the skin are synthesized by epidermal melanocytes within specialized lysosome-related organelles called melanosomes. Melanosomes coexist with lysosomes; thus, melanocytes employ trafficking machineries that possess cell-type-specific functions to ensure correct cargo delivery to either the endolysosomal system or maturing melanosomes. Mutations in some of the protein complexes required for melanogenic cargo delivery, such as biogenesis of lysosome-related organelles complex 1 (BLOC-1), result in hypopigmentation due to mistrafficking of cargo to endolysosomes. We show that hypopigmented BLOC-1-deficient melanocytes retain melanogenic capacity that can be enhanced by treatment with cyclic adenosine monophosphate (cAMP)-elevating agents despite the mislocalization of melanogenic proteins. The melanin formed in BLOC-1-deficient melanocytes is not generated in melanosomes but rather within late endosomes/lysosomes to which some cargoes mislocalize. Although these organelles generally are acidic, a cohort of late endosomes/lysosomes have a sufficiently neutral pH to facilitate melanogenesis, perhaps due to mislocalized melanosomal transporters and melanogenic enzymes. Modulation of the pH of late endosomes/lysosomes by genetic manipulation or via treatment with lysosomotropic agents significantly enhances the melanin content of BLOC-1-deficient melanocytes. Our data suggest that upregulated expression of mistargeted cargoes leads to both increased tyrosinase expression and subsequent activity due to pH modulation facilitating the reprogramming of a subset of endolysosomes to replicate some functions of lysosome-related organelles.

Indexed as

Carrier ProteinsEndosomesLysosomesMelaninsMelanocytesMelanosomesAnimalsCyclic AMPMelanogenesisMiceCarrier ProteinsCyclic AMPMelaninsBLOC-1Hermansky-Pudlak syndromelate endosomeslysosomesMC1R signalingmelanogenesispH modulationpigmentation

Identifiers

PMID40683250
PMCPMC12320751

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.